title: On the mechanism determining the TH1/TH2 phenotype of an immune response, and its pertinence to strategies for the prevention, and treatment, of certain infectious diseases.
abstract: It is well recognized that the physiological/pathological consequences of an immune response, against a foreign or a self-antigen, are often critically dependent on the class of immunity generated. Here we focus on how antigen interacts with the cells of the immune system to determine whether antigen predominantly generates Th1 or Th2 cells. We refer to this mechanism as the 'decision criterion' controlling the Th1/Th2 phenotype of the immune response. A plausible decision criterion should account for the variables of immunization known to affect the Th1/Th2 phenotype of the ensuing immune response. Documented variables include the nature of the antigen, in terms of its degree of foreignness, the dose of antigen and the time after immunization at which the Th1/Th2 phenotype of the immune response is assessed. These are quantitative variables made at the level of the system. In addition, the route of immunization is also critical. I describe a quantitative hypothesis as to the nature of the decision criterion, referred to as the Threshold Hypothesis. This hypothesis accounts for the quantitative variables of immunization known to affect the Th1/Th2 phenotype of the immune response generated. I suggest and illustrate how this is not true of competing, contemporary hypotheses. I outline studies testing predictions of the hypothesis and illustrate its potential utility in designing strategies to prevent or treat medical situations where a predominant Th1 response is required to contain an infection, such as those caused by HIV-1 and by Mycobacterium tuberculosis, or to contain cancers.
authors.affiliation: University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
authors.forename: P A
authors.initials: PA
authors.lastname: Bretscher
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology* / Q000517:prevention & control / Q000628:therapy; D000818:Animals; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D004912:Erythrocytes / Q000276:immunology; D006801:Humans; D015847:Interleukin-4 / Q000502:physiology; D008565:Membrane Proteins; D009687:Nuclear Proteins; D010641:Phenotype; D018417:Th1 Cells / Q000276:immunology*; D018418:Th2 Cells / Q000276:immunology*; D014376:Tuberculosis / Q000276:immunology* / Q000517:prevention & control / Q000628:therapy; D044767:Ubiquitin-Protein Ligases
chemical_list: C429530:DTL protein, human; C516570:ITPRIP protein, human; D008565:Membrane Proteins; D009687:Nuclear Proteins; D015847:Interleukin-4; D044767:Ubiquitin-Protein Ligases